tbuckley/cabot-search huggingface dataset:
Council on Physical Therapy
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey
Authors: R Brian Haynes, K Ann McKibbon, Nancy L Wilczynski, Stephen D Walter, Stephen R Werre
Journal: BMJ (2005)

<h3>Abstract</h3> <b>Objective</b> To develop and test optimal Medline search strategies for retrieving sound clinical studies on prevention or treatment of health disorders. <b>Design</b> Analytical survey. <b>Data sources</b> 161 clinical journals indexed in Medline for the year 2000. <b>Main outcome measures</b> Sensitivity, specificity, precision, and accuracy of 4862 unique terms in 18 404 combinations. <b>Results</b> Only 1587 (24.2%) of 6568 articles on treatment met criteria for testing clinical interventions. Combinations of search terms reached peak sensitivities of 99.3% (95% confidence interval 98.7% to 99.8%) at a specificity of 70.4% (69.8% to 70.9%). Compared with best single terms, best multiple terms increased sensitivity for sound studies by 4.1% (absolute increase), but with substantial loss of specificity (absolute difference 23.7%) when sensitivity was maximised. When terms were combined to maximise specificity, 97.4% (97.3% to 97.6%) was achieved, about the same as that achieved by the best single term (97.6%, 97.4% to 97.7%). The strategies newly reported in this paper outperformed other validated search strategies except for two strategies that had slightly higher specificity (98.1% and 97.6% <i>v</i> 97.4%) but lower sensitivity (42.0% and 92.8% <i>v</i> 93.1%). <b>Conclusion</b> New empirical search strategies have been validated to optimise retrieval from Medline of articles reporting high quality clinical studies on prevention or treatment of health disorders.
Yes Sir, no Sir, not much difference Sir
Authors: Mike Clarke, Lorcan Clarke, Thomas Clarke
Journal: Journal of the Royal Society of Medicine (2007)

Objective To assess whether making the sender's knighthood explicit in a series of letters would have any detectable effect on the response. Design A random sequence was generated by flipping a coin to determine whether a letter would have ‘Sir Iain Chalmers’ or ‘Iain Chalmers’ typed under the signature. This sequence was prepared independently of the preparation of an alphabetic list of the intended recipients and was then used to determine which letter would be sent. The allocation could not be influenced by prior knowledge of the recipient. Two batches of letters were sent. Setting Medical royal colleges and associated faculties, and postgraduate medical and dental schools in the UK. Participants Presidents and deans of medical royal colleges and deans of postgraduate medical and dental schools in the UK. Main outcome measures Rates of response and the mean number of days between the posting of the original letter and the date on the response. Results No differences between the groups were detected in the response rates: 91% and 90% for ‘Sir Iain Chalmers’ and ‘Iain Chalmers’ (relative rate for response of 1.01, 95%CI 0.83–1.23, P=0.92), or in the mean number of days to response (‘Sir’: 32 days; ‘no Sir’: 33 days). Conclusions This finding is consistent with a systematic review of responses to postal surveys, in which the effect of the status of the signatory was investigated. Combining our result with the two trials that are most comparable to our study, in which letters from professors were compared with letters from students, gives a relative response rate of 1.00 (95% CI 0.91–1.10, P=0.99). There is, therefore, no evidence from the existing randomized experiments that the status of the signatory has any impact on the likelihood or promptness of response—even if the status was conferred by the British monarch.
Disclaims Dishonesty.
Authors: W. B. Clarke
Journal: JAMA (1899)

Indianapolis, Ind., April 14, 1899. <h3>To the Editor:</h3> —In one of your "Minor Comments" of April 8 (videJournal, p. 770), complaint is made concerning "one W. B. Clarke" (the "one" lest there might be two, perhaps), in a published communication "made up of alleged quotations from medical men, against vaccination," in which "isolated statements are quoted from noted physicians, but separated from their context so as to make them express opinions contrary to the general tone of their published writings and their real sentiments," which presentation you characterize as "thoroughly dishonest" and characteristic of "unscrupulous cranks." Having long been a reader of theJournal, the best medical journal in the world, and not wishing to fall under its condemnation, but desiring to be set right in the matter, please allow me to say that the article you refer to was mainly made up from the work "Smallpox and Vaccination,"
EBV &amp; lymphoma
Authors: Dolores Caballero
Journal: HemaSphere (2019)

Learning goals Pathogenesis of EBV lymphoproliferative disorders WHO 2016 update of EBV disorders Management of disorders associated to EBV mutagenic effect including solid and hematopoietic stem cell PTLD. Introduction EBV virus is a ubiquitous virus infecting up to 95% of the population. The consequences of this infection range from a benign course to very aggressive Lymphomas. EBV virus was recognized as the cause in the pathogenesis of endemic Burkitt lymphoma in the 1960s, a very aggressive disease but highly curable with chemotherapy; now EBV is considered the most oncogenic virus. Following infection, the virus will remain on the host, keeping in B cells. Transformation of B cells by virus is mainly driven by two genes: LMP1 and EBNA2. Different latency patterns will be responsible for the evolution of patients infected. Recently the WHO 2016 lymphoma classification has added several entities to these complex EBV lymphoproliferative disorders with up to 20 subtypes included. In situ hybridization for EBERs is the most sensitive test for EBV infection in tissue. The diagnosis of different subtypes is crucial for the correct patient management. The importance of the immune system in the pathogenesis and the evolution is demonstrated by the role of intensity in the treatment of post-transplant EBV lymphoproliferative disorders (PTLD); it is important to point it out that up to PTLD could not be associated to EBV. In this educational session, EBV associated lymphoproliferative disorders and PTLD will be reviewed in terms of diagnosis, pathogenesis, and management.
Error in Optimized Calcium Dosage Shown in Table 2 of the Article by Buckley et al (Arthritis Rheumatol, August 2017)
Journal: Arthritis & Rheumatology (2017)

lymphoma in a context of accumulated immunosuppression.In our study the involvement of RTX therapy was very likely, since the onset of KS or primary effusion lymphoma occurred a few months after the first infusion and no other immunosuppressive drug was added.In addition, 3 patients developed visceral KS or primary effusion lymphoma with life-threatening disease.RTX is known to be associated with a welltolerated safety profile.A long-term follow-up study in RA has confirmed a consistent safety profile for RTX over time up to 11 years of follow-up for 3,595 patients.The overall serious infection event rate was 3.76/100 patient-years, and serious opportunistic infections remained infrequent (15).Even if these severe adverse events are rare, vigilance is needed, particularly for immunocompromised patients.We did not observe HHV-8 tumors after treatment with tocilizumab, TNF inhibitors, or other biologic agents.However, other immunosuppressive therapies, such as CYC, methotrexate, and corticosteroids, are prone to induce HHV-8 tumors in patients who are at risk.In conclusion, physicians should screen patients for risk of KS (high phototype corresponding to dark skin) and perform pretreatment serologic testing for HHV-8 to avoid development of RTX-induced HHV-8 tumors.The safety of RTX, especially in nonlymphomatous disorders, such as autoimmune and systemic inflammatory diseases, needs to be carefully evaluated in patients at risk of HHV-8 tumors.
Encéphalite Hyperthermique.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>KRAS</i> amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).
Authors: Joseph Chao, Russell Madison, Jeffrey S. Ross, Vincent A. Miller, Siraj Mahamed Ali, Alexa Betzig Schrock, Samuel Jacob Klempner
Journal: Journal of Clinical Oncology (2019)

e15565 Background: KRAS mutations are common oncogenic events across cancers, but effective RAS-directed therapies are lacking. However, recent studies support use of PD-1 blockade in most subsets of lung cancer with KRAS short variant mutations (KRAS SV ) (PMID: 28039262), and preclinical data supports combined MEK and SHP2 inhibition in KRAS amplified ( KRAS a ) GEA (PMID: 30093730). We sought to explore the landscape of KRAS altered GEA and compare genomic profiles of KRAS-altered and KRAS wild-type (WT) cases for biomarkers of response to targeted therapies and immune checkpoint inhibitors. Methods: 6,667 tissue specimens from patients with advanced GEA were assayed using hybrid capture-based comprehensive genomic profiling. Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 95 or 114 loci. Descriptive statistics were used to compare among subgroups. Results: KRAS SV and KRAS a were identified in 11% and 5.8% of gastric adenocarcinoma (GA), respectively, and in 7.2% and 17% of esophageal adenocarcinoma (EA), respectively. KRAS a and KRAS SV were nearly mutually exclusive, co-occurring in only 4.4% of KRAS altered cases. ERBB2 alterations were less common in KRAS SV and KRAS a GEA (both 9%) as compared with KRAS WT GEA (19%) (p = 1.9E-16). EGFR a was less common in KRAS SV vs KRAS a GEA (1.9% vs 9.3%, p = 2.6E-8), whereas PIK3CA SV was more common in KRAS SV vs KRAS a (16% vs 5.0%, p = 1.5E-11). Median TMB for all groups was similar; however, KRAS SV GEA had a higher mean TMB (9.7 mut/Mb) as compared to KRAS a (5.1 mut/Mb, p = 5.0E-12) and KRAS WT cases (5.8 mut/Mb, p = 2.2E-07). KRAS codon 12/13 accounted for &gt; 80% of predicted pathogenic mutations. MSI-high was also more prevalent in KRAS SV (11.3%) vs KRAS a (0.9%, p = 4.8E-15) and KRAS WT GEA (2.4%, p = 1.8E-25). MSI-high KRAS SV GEA was associated with older patient age (median 72 years) and with high TMB (median 40.9 mut/mb). Conclusions: GA was enriched for KRAS mutation whereas EA was enriched for KRAS amplification. KRAS WT vs KRAS SV vs KRAS a each presented distinct genomic profiles. KRAS a in the absence of KRAS mutation exists in 11% of GEA and warrants further exploration to inform combination treatment strategies.
Books Received.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rape victim advises report attack, get help
Authors: D. Riesenberg
Journal: JAMA (1987)

ACCOMPANIED BY her counselor, a rape survivor—a woman in her mid-20s—agreed to talk with<i>JAMA</i>MEDICAL NEWS &amp; PERSPECTIVES about her experience. She told of the chance meeting with a male acquaintance after work one night more than a year ago. As they walked near her home, the man suggested they go into a deserted park and talk for a while. Once there, he began forcibly fondling her. When she resisted, he threatened to hurt her, pulled off some of her clothing, and raped her. The victim broke loose, ran out of the park, and began knocking on doors across the street. No one answered; she ran several blocks before spotting a police car. The officers were unable to locate the attacker; they took the victim to a hospital. <i>How did you manage to break away from your attacker?</i>"At first, I tried to reason with him, but he started
Social Medicine and Medical Economics
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PRESIDENT ROOSEVELT AND A DEPARTMENT OF PUBLIC HEALTH.
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE ADMINISTRATION OF FLUIDS BY INTRAPERITONEAL INFUSION
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug Combo Shows Promise in NRAS-Mutant Melanoma
Journal: Cancer Discovery (2014)

Abstract Binimetinib plus LEE011 shows early promise against NRAS-mutant melanoma, for which no effective therapies currently exist. By simultaneously inhibiting MEK1/2 and CDK4/6, thereby inducing apoptosis and blocking cell proliferation, the drug combination better mimics direct inhibition of RAS.
Abstract 15192: Leptin Effects on Osteoblast Differentiation of Human Valvular Interstitial Cells: New Insight Into Calcific Aortic Valve Disease
Authors: Mickael Rosa, Rodrigo Lorenzi, Madjid Tagzirt, Francis Juthier, Antoine Rauch, Ramadan Jashari, Delphine Corseaux, Bart Staels, Eric Van Belle, Sophie Susen, Annabelle Dupont
Journal: Circulation (2015)

Introduction: Calcific aortic valve disease (CAVD) affects 2% to 6% of the population over 65 years and results from dysregulated processes such as calcification, supported in part by the osteoblast differentiation of valvular interstitial cells (VIC), the most prevalent cell type in the human aortic valves. Leptin has recently been linked to aortic valve calcification in ApoE-/- mice. Hypothesis: Our hypothesis is that leptin could play a role in the calcifying processes implicated in CAVD via direct effects on human VIC. Methods: Patients who underwent aortic valve replacement for severe CAVD (n=43) or with coronary artery disease (CAD) but without CAVD (n=129) were included in this study. Presence of leptin was analyzed in human explanted calcified aortic valves and blood samples. Leptin receptors expression was analyzed in aortic valves and VIC isolated from aortic valves. Leptin effects on osteoblast differentiation of VIC in presence or not of Akt and ERK inhibitors were investigated by alizarin red staining, alkaline phosphatase (ALP) activity, and RT-qPCR analysis for osteopontin, ALP, bone morphogenetic protein BMP-2, and RUNX2. Results: Patients with CAVD have significant higher serum leptin concentration than CAD patients (p=0.002). The presence of leptin was observed by immunochemistry in human calcified aortic valves, with higher concentrations in calcified vs non-calcified zones (p=0.01). Both short and long leptin receptor isoforms were expressed in VIC. Chronic leptin stimulation of VIC enhanced ALP, BMP-2 and RUNX2 expression and decreased osteopontin expression. This treatment led to a higher, dose dependent, ALP activity and calcium deposition in VIC. Inhibiting Akt or ERK during leptin stimulation led to a reduced calcification by bringing the expression of calcification genes to the control levels. Conclusions: Together, these novel findings depict the potential role of leptin in the process of CAVD by triggering calcification processes in human VIC.